Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, announced it has secured $20 million in Series A financing, bringing its total funding to $27 million.
The Series A round was led by McKesson Ventures, with participation from SignalFire. Existing investors include Iaso Ventures, Virtue, and GV. This investment follows a $7 million seed round completed in 2024.
Prudentia Sciences provides an AI-native platform designed to enable pharmaceutical companies, biotechs, and financial institutions to evaluate breakthrough medicines with enhanced speed and rigor. The platform synthesizes complex clinical signals into actionable insights, aiming to accelerate deal throughput and provide strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach is designed to orchestrate collaboration between buyers, sellers, and intermediaries, ensuring a secure and compliant infrastructure for investment decisions.
Dave Schulte, President of McKesson Ventures, commented on the development, stating that Prudentia is modernizing how life sciences organizations utilize data to evaluate assets and manage risk. He highlighted the platform’s ability to accelerate scientific due diligence with real-time insights, seamless integration, and intelligent automation, transforming a traditionally fragmented process into a connected workflow.
The new capital will be used to expand Prudentia Sciences’ product capabilities, deepen intelligence for both technical and non-technical diligence, and scale commercial operations. This includes planned expansion into the Asia-Pacific and European markets. Prudentia aims to create a single, continuously updated source of truth for diligence, allowing teams to align faster and make high-stakes investment and partnering decisions with the support of explainable AI.
Sadiqa Mahmood, Founder and CEO of Prudentia Sciences, noted the inherent complexity and time-intensive nature of life sciences dealmaking, where substantial capital and scientific innovation are at stake. She explained that biotechs often face challenges in presenting their assets with clarity, while pharma teams must balance speed with thorough diligence. Mahmood added that without an intelligent platform to bridge this gap, diligence processes can remain fragmented and high-risk. Prudentia, she stated, aims to collapse the distance between technical data and strategic conviction, enabling teams to make confident go-or-no-go decisions more rapidly.
